CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30 September 2026. Continued progress in customer contracting and the development of CDC’s capacity pipeline was offset by the macroeconomic impact of

The Company announces that, on 6 October 2026, it purchased for cancellation 202,000 Ordinary shares of 5 pence each in the Company ("Shares") at a price of 339.00 pence per Share

US stocks extended their gains overnight, with the S&P 500 up 0.8%, the Nasdaq up 1.2% and the Russell 2000 up 0.9%. Every sector except real estate rose. Materials and energy led, helped by a roughly 6% jump in steel stocks

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company, today announces sustained double-digit revenue growth for 1H FY27. It also reports it remains on track to deliver its FY27 $300 million revenue target

The Company announces that, on 5 October 2026, it purchased for cancellation 235,000 Ordinary shares of 5 pence each in the Company ("Shares") at a price of 339.21 pence per Share

What does this mean for the outlook for the New Zealand and Australian stock markets?

If you have listed NZX and ASX investments and you are in the process of reassessing your holdings or wish to do so, our advisers at Equity Investment Advisers Limited are willing to assist. As you are no doubt aware most markets are fully priced, and som